Avirmax, Inc.

ABI-201 is developed to achieve durable and effective treatment of dry AMD and the other retina disorders by a single intravitreal injection. @dry AMD, @antiinflammation and @ photoreceptor protection

The February edition of Market Scope’s Ophthalmic Market Perspectives newsletter has been published! This edition features curated coverage of Glaucoma Research Foundation's Glaucoma 360 New Horizons Forum highlighting innovations and discussing the future of glaucoma therapy; Bausch + Lomb ruling out a sale after concluding bid process; and ophthalmic officials, doctors, and researchers feeling the effects of President Trump’s sweeping changes. This issue also covers Norlase strengthening its position in the ophthalmic laser market with the launch of the Lynx LIO, EssilorLuxottica acquiring Canadian retinal camera maker Cellview Imaging, Australian regulators approving Apellis Pharmaceuticals’ Syfovre for patients with GA, a US appeals court upholding injunctions blocking #Eylea biosimilars, Oculis leading the latest ophthalmic fundraising with a $100M offering, the US FDA approving an expanded label for Astellas Pharma's Izervay to extend treatment for GA beyond 12 months, NovaBay Pharmaceuticals gaining shareholder approval to sell its eye care business, Harrow and Cencora partnering to improve drug access for retina specialists and patients, and the global OCT market being poised for strong growth thanks to add-ons. It also examines studies finding a link between IVT injections and cataract surgery complications and the promise for genetic base editing in Stargardt disease. This edition also identifies SeaBeLife Biotech and Next Generation Gene Therapeutics as emerging companies pursuing ophthalmic indications and provides clinical trial updates from Ocugen, IView Therapeutics, Qlaris Bio, Inc., EyePoint Pharmaceuticals, Rayner, Avirmax, Inc., Stuart Therapeutics, Sling Therapeutics, 4D Molecular Therapeutics, and Tenpoint Therapeutics, Ltd. To subscribe to this newsletter or request a sample: ?? https://bit.ly/MSOMP? ?? [email protected] #Ophthalmology #Ophthalmic #News #Market #IndustryNews #MeetingCoverage #EmergingCompanies #ClinicalTrials #Acquisitions

Avirmax Biopharma Announces Completion of the First Cohort of Patient Enrollment in Clinical Trial of ABI-110, a Gene Therapy for Wet AMD Including PCV https://lnkd.in/gNe4Fbm5

Avirmax doses first patient in Phase I/IIa trial of ABI-110, a pioneering gene therapy for Wet AMD and PCV https://lnkd.in/g2VDFP-A

Avirmax doses first patient in Phase I/IIa trial of ABI-110, a pioneering gene therapy for Wet AMD and PCV https://lnkd.in/g2VDFP-A

We are honored to join ARVO’s Virtual Conference of Frontier Research in Ocular Gene Therapy. Dr. Shengjiang Shawn Liu, our CEO and CSO, would like to share our experiences in Avirmax Biopharma’s venture in the coming panel session.

We are honored to join ARVO’s Virtual Conference of Frontier Research in Ocular Gene Therapy. Dr. Shengjiang Shawn Liu, our CEO and CSO, would like to share our experiences in Avirmax Biopharma’s venture in the coming panel session.

We are thrilled that Dr. Liu will chair and present “VSaf-AAV manufacturing& quality”at the coming session: Acceleration of AAV gene therapy for ocular diseases: Improving delivery and quality, of the virtual Frontier in ocular gene therapy research conference, ARVO, Nov 13, 12:-13:15 pm ET.

I am thrilled to show at 2024 AAO and share our latest progresses in the innovation of complement 3 & C9 inhibitor (vsCD59) and photoreceptor protection protein, 3 GOIs in one AAVN54 vector, ABI-201, delivered via intravitreally(IVT) into monkeys. Signicantly improvement of electrophysiological activitities of rods (DA10.0) and cones (LA3.0) were achieved Fig A&B. In the mean time, ABI-201 shown strong inhibition of angiogenesis in mouse laser choroudal neovascularization LCNV) model.#gene therapy, #AAV#Avirmax Biopharma#Hayward, CA